FCPA Compliance for Medical Device Manufacturers: 2025 Shifts and Case Record

A guide to US FCPA compliance for medical device manufacturers, covering the 2025 DOJ guidelines, historical cases, distributor red flags, and QMS controls.

Why Medical Device Manufacturers Are a Top FCPA Target: The "Foreign Official" Theory

For medical device and in vitro diagnostic (IVD) manufacturers, expanding into international markets is essential for growth. However, this cross-border commercialization triggers severe legal exposures under the US Foreign Corrupt Practices Act (FCPA). Unlike general consumer-goods manufacturing, the medical technology (medtech) sector is structurally vulnerable to FCPA enforcement due to a fundamental commercial reality: abroad, health systems are frequently state-owned or state-controlled, meaning that doctors, hospital administrators, and laboratory personnel are legally classified as "foreign officials."

Under the FCPA (15 U.S.C. §§ 78dd-1, et seq.), it is a federal crime for US companies, issuers, or any person acting on their behalf to offer, pay, promise, or authorize the payment of anything of value to a foreign official to secure an improper business advantage. In the United States, healthcare compliance is governed by the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), which we discuss in detail in our guide on DOJ medical device fraud enforcement: FCA and Anti-Kickback risks. Outside the US, however, the DOJ and SEC apply the FCPA extraterritorially, leveraging a legal theory first established in the healthcare sector in 2002: that physicians and procurement officers employed by public hospitals or national health insurance systems (such as the NHS in the UK, public social security institutes in Latin America, or municipal health commissions in Asia) are "foreign officials."

As a result, typical commercial practices that might be scrutinized as kickbacks domestically become international criminal bribery investigations. These include providing travel sponsorships to key opinion leaders (KOLs), offering volume-based distributor discounts that are diverted into offshore slush funds, donating equipment to public clinics to lock in high-margin consumable sales, or paying consulting fees to doctors to influence public tenders. Over the past two decades, every major orthopedic, imaging, endoscopy, and diagnostics manufacturer has resolved major FCPA actions, resulting in hundreds of millions of dollars in penalties and years of intrusive corporate monitors.

This guide provides a comprehensive compliance manual for medtech executives, legal counsel, and commercial managers. It details the statutory foundation of the FCPA, compiles the definitive history of medical device FCPA enforcement, analyzes the major 2025 DOJ enforcement policy shifts, identifies the highest-risk payment patterns in international channels, and outlines a defensible compliance framework under the latest guidance.

Key Definitions in MedTech FCPA Compliance

Understanding the boundaries of the FCPA requires familiarity with the statutory terminology as interpreted by the DOJ and SEC:

Term	Definition in the MedTech Context
Issuer	Any company with a class of securities registered under Section 12 of the Securities Exchange Act of 1934 or required to file reports under Section 15(d) (e.g., publicly traded medical device companies on US exchanges).
Domestic Concern	Any individual who is a citizen, national, or resident of the US, or any corporation, partnership, association, or sole proprietorship which has its principal place of business in the US, or which is organized under the laws of a state of the US.
Foreign Official	Any officer or employee of a foreign government or any department, agency, or instrumentality thereof. In medtech, this includes physicians, surgeons, nurses, pharmacists, lab technicians, hospital directors, and procurement committee members employed by public hospitals, universities, or ministries of health.
Instrumentality	An entity controlled by a foreign government. Factors include ownership, control, funding, and public function. State-owned enterprise (SOE) hospitals, regional public clinics, and national tender boards are instrumentalities of the state.
Anything of Value	Broadly construed to include cash, gifts, travel, meals, entertainment, charity donations, research grants, consulting contracts, product discounts, free equipment, internships for relatives, and sponsorships.
Books and Records Provisions	Section 13(b)(2)(A) of the Exchange Act, requiring issuers to make and keep books, records, and accounts which, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets. Bribes misclassified as "distributor discounts" or "marketing fees" violate this provision.
Internal Controls Provisions	Section 13(b)(2)(B) of the Exchange Act, requiring issuers to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances that transactions are executed and assets accessed only with management authorization.

What Actually Changed in 2025: EO 14209, the Bondi Memo, and the June 9 DOJ Guidelines

Enforcement of the FCPA underwent a significant structural pivot in 2025. This shift altered the prioritization of cases and the risk calculus for companies deciding whether to self-disclose compliance violations.

The 2025 Enforcement Pause (EO 14209)

On February 10, 2025, President Trump signed Executive Order 14209, titled "Pausing Foreign Corrupt Practices Act Enforcement to Further American Economic and National Security." This executive order directed the DOJ and SEC to pause ongoing and new FCPA investigations and enforcement actions for up to 180 days. It established a hard requirement that any new FCPA enforcement action or settlement require the personal, written approval of the Attorney General.

The purpose of the order was to review whether the historical, aggressive enforcement of the FCPA placed US medical device and pharmaceutical companies at a competitive disadvantage against non-US firms (particularly European and Asian competitors) that were not subject to similar extraterritorial restrictions. On February 5, 2025, a companion memorandum from the new administration (the "Bondi Memo") signaled that white-collar enforcement resources would be redirected toward prosecuting transnational organized crime, drug cartels, and national security threats.

The June 9, 2025 DOJ FCPA Guidelines

The 180-day pause did not result in the permanent repeal of the FCPA. Instead, 119 days into the pause, on June 9, 2025, Deputy Attorney General Todd Blanche issued the landmark memorandum, "Guidelines for Investigations and Enforcement of the FCPA." These Guidelines officially ended the enforcement pause and established a new, highly targeted framework for prioritizing FCPA cases.

The June 2025 Guidelines direct prosecutors to focus resources on cases that satisfy at least one of four prioritization factors:

Safeguarding Fair Opportunities for US Companies: Prosecuting bribery schemes where foreign competitors bribe local officials to squeeze out US medical device manufacturers from public tenders.
Protecting US National Security: Targeting corruption that undermines critical supply chains or involves sensitive, dual-use medical and diagnostic technologies.
Addressing Serious Misconduct: Focusing on high-dollar, systemic, or executive-led corporate bribery schemes, rather than isolated, low-level payments by remote distributors.
Prioritizing Cartels and Transnational Criminal Organizations (TCOs): Targeting corruption directly linked to international crime networks, illicit trade, or money laundering.

For medical device companies, this means that while routine, administrative "grease payments" or minor local hospitality errors are less likely to trigger a multi-agency federal investigation, systemic distributor-led bribery schemes designed to win major national hospital tenders remain a high priority under the "fair opportunities" and "serious misconduct" prongs.

The Revised Corporate Enforcement Policy (May 12, 2025)

Preceding the June Guidelines, on May 12, 2025, the DOJ Criminal Division updated its Corporate Enforcement and Voluntary Disclosure Policy. This revised policy strengthened the incentives for companies to self-disclose violations:

Presumption of Declination: If a medical device manufacturer voluntarily self-discloses an FCPA violation before it becomes known to the government, fully cooperates with the investigation, and implements comprehensive remediation, there is a strong presumption that the DOJ will issue a declination (closing the file without prosecution), even if aggravating circumstances are present.
Individual Accountability: The policy reinforces that to secure cooperation credit, the corporation must identify and provide all non-privileged facts regarding the individuals involved in the misconduct, including foreign distributors, local sales managers, and complicit public hospital physicians.
Penalty Reductions: For companies that do not self-disclose but subsequently fully cooperate and remediate, the DOJ offers up to a 50% reduction off the low end of the U.S. Sentencing Guidelines fine range, a substantial change from prior policy limits.

The MedTech FCPA Enforcement Record: Major Case Analysis

The historical record demonstrates that medical device manufacturers are among the most heavily penalized entities under the FCPA. The table below compiles the major resolved enforcement actions in the sector, detailing the agencies involved, the financial penalties, the countries where the misconduct occurred, and the underlying corrupt mechanics.

Definitive MedTech FCPA Enforcement Table

Company (Year)	Resolving Agencies	Total Financial Resolution	Primary Countries Involved	Corrupt Mechanics & Payment Channels	Compliance Monitor
Fresenius Medical Care (2019)	DOJ / SEC	$231.7 Million (DOJ: $84.7M penalty) (SEC: $147M disgorgement)	Spain, China, Angola, Saudi Arabia, Morocco, Turkey, West Africa	Paid bribes to public clinic directors and nephrologists through sham consulting agreements, slush funds, and joint-venture buyouts to secure dialysis machine contracts.	2-Year Independent Monitor
Johnson & Johnson (2011)	DOJ / SEC	$70.0 Million (DOJ: $21.4M criminal) (SEC: $48.6M disgorgement)	Greece, Poland, Romania	Routed cash bribes through Greek shell-company distributors to publicly employed orthopedic surgeons to select J&J implants; paid travel and consulting fees in Poland and Romania.	3-Year Self-Reporting Requirement
Bio-Rad Laboratories (2014)	DOJ / SEC	$55.0 Million (DOJ: $14.3M penalty) (SEC: $40.7M disgorgement)	Russia, Vietnam, Thailand	Paid 15-30% commissions to intermediaries who maintained offshore bank accounts; bribes routed to public lab managers to clear high-value diagnostics tenders.	2-Year Self-Reporting Requirement
Zimmer Biomet (2017)	DOJ / SEC	$30.4 Million (DOJ: $17.4M criminal) (SEC: $13.0M disgorgement)	Brazil, Mexico	Breached 2012 DPA. Continued using a known corrupt distributor in Brazil who paid bribes to public surgeons; paid bribes via sham consulting fees to Mexican doctors.	3-Year Independent Monitor
Biomet (2012)	DOJ / SEC	$22.8 Million (DOJ: $17.28M penalty) (SEC: $5.57M disgorgement)	Argentina, Brazil, China	Paid commissions of 10-20% of sales to public orthopedic surgeons; recorded payments as "consulting fees," "royalties," or "scientific incentives."	18-Month Independent Monitor
Olympus Latin America (2016)	DOJ	$22.8 Million (Criminal penalty only)	Brazil, Argentina, Colombia, Costa Rica	Maintained "miles programs" and travel funds to sponsor personal vacations for public hospital physicians; paid cash bribes disguised as medical society sponsorships.	3-Year Independent Monitor
Smith & Nephew (2012)	DOJ / SEC	$22.2 Million (DOJ: $16.8M criminal) (SEC: $5.4M disgorgement)	Greece	Routed extra 25-35% distributor discounts to offshore shell companies owned by a Greek distributor, who used the cash to bribe public hospital surgeons.	18-Month Independent Monitor
Analogic & BK Medical (2016)	DOJ / SEC	$14.9 Million (DOJ: $3.4M criminal) (SEC: $11.5M disgorgement)	Russia, Ukraine, Netherlands	BK Medical (subsidiary) provided inflated distributor discounts to Russian partners, who routed the difference to shell companies to bribe state medical clinic officials.	3-Year Self-Reporting Requirement
Stryker Corporation (2013)	SEC	$13.2 Million (SEC: $3.5M penalty) (SEC: $9.7M disgorgement/interest)	Argentina, Greece, Mexico, Romania, Poland	Paid public doctors for "consulting" services that were never performed; sponsored lavish, non-scientific travel; falsified books to hide payments.	Compliance Consultant Required
Stryker Corporation (2018)	SEC	$7.8 Million (SEC penalty only)	India, China, Kuwait	Second SEC Settlement. Failed to maintain sufficient internal controls over dealer/distributor pricing, permitting unauthorized discounts that created local bribe pools.	3-Year Compliance Consultant

Where the Money Hides: Device-Specific Bribe Patterns & Red Flags

Unlike direct cash handoffs, corruption in the medical device industry is typically embedded in standard commercial workflows. Compliance audits must target these five high-risk payment patterns:

[Manufacturer]
       │
       ▼ (Inflated Discount, e.g., 30% extra)
[Distributor / Dealer]
       │
       ├─► [Offshore Shell Company / Slush Fund]
       │         │
       │         ▼ (Cash or Lavish Travel)
       └─► [State Hospital Doctor / Tender Board] (Improper Influence)

1. The Distributor Discount/Margin Pool Scheme

The single most common mechanism for creating bribe funds in medtech is the manipulation of distributor margins. In many international markets, manufacturers do not sell directly to hospitals; instead, they sell to local distributors at a discount (e.g., 40% off list price), and the distributor resells the device to the hospital.

The Bribe Mechanism: The manufacturer grants an unauthorized or inflated discount (e.g., 70% off list), reducing its own margins. The distributor sells the product to the public hospital at the standard list price. The distributor routes the excess margin (the "spread") to an offshore bank account or shell company, using those funds to pay cash bribes to the public hospital procurement committee.
Medtech Example (Smith & Nephew): Smith & Nephew's Greek subsidiary sold reconstruction implants to a distributor at a standard discount, but also routed a portion of the discount to a shell company in the UK. The distributor used these UK funds to pay cash incentives directly to Greek public hospital doctors.
Audit Red Flag: Distributors requesting margins that deviate significantly from historical averages or regional benchmarks (e.g., a request for a 65% discount when the regional average is 35%) without a documented, verified justification (such as extensive local clinical training obligations).

2. Sham Key Opinion Leader (KOL) & Consulting Contracts

Medical device companies routinely retain physicians to help design prototypes, conduct clinical trials, or speak at educational symposia. This is a legitimate practice, often governed by design transfer procedures such as those described in our supplier quality management medical devices guide.

The Bribe Mechanism: A public hospital surgeon is signed to a consulting contract with a high hourly rate, but the physician does not perform any actual services, or the services are drastically overvalued. The consulting contract is a pretext to pay the physician for choosing the company's implants for their hospital's operating rooms.
Medtech Example (Biomet): Biomet paid public hospital orthopedic surgeons in Argentina and China "consulting fees" calculated as a flat percentage of the value of the implants the surgeons purchased for their hospitals.
Audit Red Flag: Consulting agreements where the deliverables are vague (e.g., "market feedback reports" that are only one page long), where the compensation exceeds Fair Market Value (FMV) benchmarks, or where the consulting fee is paid to a surgeon who chairs the hospital's tender committee.

3. Sponsoring Travel and Scientific Events

Continuing medical education (CME) is critical in medtech, particularly for complex Class III devices like cardiac pacemakers or surgical robots. Sponsoring physicians to attend conferences is common.

The Bribe Mechanism: The educational sponsorship is used as a cover for personal vacation travel. The manufacturer pays for first-class flights, five-star luxury resorts, and entertainment for the physician and their spouse, with little to no attendance at the actual scientific sessions.
Medtech Example (Olympus Latin America): OLA created a training fund where regional sales managers could deposit a percentage of sales. These funds were used to sponsor public hospital physicians' personal travel to tourist destinations in Europe and the US, bypassing the company's standard approval channels.
Audit Red Flag: Travel requests where the destination is a resort during peak season, where the itinerary includes days of leisure that exceed the duration of the scientific conference, or where the sponsor pays for the travel of spouses or family members.

4. Charitable Donations and Equipment Placements

To build local goodwill, device companies often donate equipment to public clinics or sponsor medical societies.

The Bribe Mechanism: A donation is made to a charity or foundation managed directly by a public hospital director or their family member. Alternatively, the company provides a public hospital with "free" capital equipment (such as an immunoassay analyzer) under a reagent rental or consignment agreement. The hospital procurement board then commits to purchasing the high-margin consumable assays from the donor at inflated prices, with a portion of those profits routed back to the board members.
Audit Red Flag: Donations requested by a customer during active tender negotiations, donations made to charities that lack official tax-exempt status, or free capital placements that are not backed by a signed, commercially reasonable reagent agreement.

5. Consignment Stock and "Free" Implants

Orthopedic and cardiovascular devices are frequently managed as consignment stock, stored directly in the hospital's cleanrooms and billed only when used.

The Bribe Mechanism: The manufacturer or distributor intentionally "over-ships" consignment stock or fails to audit inventory, allowing the hospital staff to use implants without billing them, or permitting surgeons to take implants for private, off-book procedures. Alternatively, the manufacturer provides "free" implants to a doctor's private practice as an incentive to use the company's brand in their public hospital work.
Audit Red Flag: Consignment accounts with high inventory write-offs, lack of regular physical inventory counts by independent company personnel, or discrepancy rates between clinical usage logs and billing invoices.

Building a Defensible Third-Party Compliance Program

Under the revised 2025 DOJ guidelines and the eCFR internal-controls provisions, a medical device company cannot defend itself by claiming it was unaware of its distributors' corrupt actions. If the manufacturer failed to implement reasonable due diligence and transaction controls, it is liable.

A defensible international compliance program must cover these three operational phases:

[Phase 1: Onboarding] ──► [Phase 2: Execution] ──► [Phase 3: Audit]
  - Tiered Diligence        - FMV Review             - Data-Driven Audits
  - Red-Flag Resolution     - Split-Payment Ban      - Distributor Testing
  - Standard Clauses        - Consignment Audits     - Transaction Reconciliations

Phase 1: Due Diligence and Onboarding

Before signing a distribution agreement in an international market, the manufacturer must execute a tiered due-diligence review:

Tiered Diligence Questionnaires: Every distributor must disclose their ownership structure, identify any relationships with government officials or public hospital employees, and provide list-price and hospital-bid histories.
Independent Background Checks: Utilize third-party compliance databases (e.g., World-Check, Dow Jones Risk & Compliance) to search for politcally exposed persons (PEPs), previous corruption allegations, or government sanctions.
Red-Flag Resolution: Any red flags—such as a distributor refusing to sign anti-bribery representations, requesting payments to third-party bank accounts, or lacking local offices or regulatory credentials—must be formally resolved and documented by the Chief Compliance Officer before contract signing.
Standard Contractual Clauses: Every distribution agreement must contain:
- Mandatory compliance with the FCPA and local anti-bribery laws.
- Right-to-audit clauses permitting the manufacturer to inspect the distributor's books, bank statements, and hospital invoices.
- Immediate termination rights without compensation if the distributor violates anti-bribery provisions.

For guidance on structuring these contracts, consult our guide on medical device distribution agreements: regulatory clauses and importer duties.

Phase 2: Transaction and Price Controls

A compliance program must control how money flows through the channel:

Fair Market Value (FMV) Review: Implement a standardized FMV calculator for all consultant, KOL, and investigator payments. Establish caps based on specialty, experience, and local economic data (e.g., regional physician salary databases).
Strict Discount Approvals: Define a matrix of authorized discounts. Any discount exceeding the baseline (e.g., more than 40% off list) must require a written business case (such as competing in a high-volume national public tender) and dual-signature approval from the CFO and Compliance Officer.
Anti-Split Payment Rules: Prohibit payment of commissions or distributor balances to multiple bank accounts, offshore financial centers, or third parties. All payments must be made to the entity's primary, local corporate account.
Consignment Audits: Conduct quarterly physical audits of all international consignment locations, cross-checking physical serial numbers against hospital usage records and invoice logs.

Phase 3: Continuous Monitoring and Auditing

Do not treat compliance as a paper-only exercise. Execute data-driven reviews:

Distributor Audits: Annually audit high-risk distributors. Exercise the contractual right-to-audit to inspect the distributor's actual selling prices to public hospitals. Verify that the distributor did not resell the product at a price that creates an unexplained, excessive margin.
Transaction Reconciliation: Reconcile discount authorizations against the final invoices. Ensure that special discounts approved for specific tenders were actually applied to those tenders, rather than used to build general slush funds.
Compliance Training: Provide mandatory, localized anti-bribery training to all international sales personnel and distributor staff. The training must cover local regulatory expectations, such as the China-specific hospital entry rules discussed in our China medical device distributor and CSO compliance audit checklist.

The Voluntary Self-Disclosure Decision Matrix

If a medical device company discovers that an international distributor has paid bribes to public hospital doctors, executive management must navigate a high-stakes decision: Should the company voluntarily self-disclose the violation to the DOJ and SEC under the May 2025 revised policy?

This decision should be guided by a structured risk-and-benefit framework:

                  ┌───────────────────────────────┐
                  │   Did the company discover   │
                  │   misconduct internally?      │
                  └───────────────┬───────────────┘
                                  ▼
                  ┌───────────────────────────────┐
                  │ Are the following true?       │
                  │  1. Prior to government       │
                  │     awareness?                │
                  │  2. Full cooperation?         │
                  │  3. Comprehensive QMS/        │
                  │     compliance remediation?   │
                  └───────────────┬───────────────┘
                                  ├──────────────────────────────┐
                                  ▼ (Yes)                        ▼ (No)
                  ┌───────────────────────────────┐  ┌──────────────────────────┐
                  │     Presumption of            │  │ High Risk of Prosecution │
                  │  Declination / NPA Path       │  │  - Up to 50% fine cap    │
                  │  - Avoid corporate monitor    │  │  - Risk of monitor       │
                  │  - Lower financial penalties  │  │  - Potential debarment   │
                  └───────────────────────────────┘  └──────────────────────────┘

The Case for Self-Disclosure (The Declination Path)

Protection from Prosecution: Under the May 2025 policy, if the disclosure occurs before the government learns of the misconduct (via a whistleblower, a competitor, or a parallel investigation), the DOJ begins with a presumption of a declination. This avoids a criminal information or deferred prosecution agreement.
Avoiding a Corporate Monitor: Monitors are incredibly expensive, often costing tens of millions of dollars, and they disrupt international operations. Securing a declination or non-prosecution agreement (NPA) almost always eliminates the monitor requirement.
Mitigating Exclusion and Debarment: A criminal conviction or guilty plea can lead to debarment from government procurement programs, which would devastate a device company's international business. A declination or civil settlement protects the company's ability to participate in public tenders.

The Case Against Self-Disclosure (The Investigation Cost)

The Cost of Cooperation: Voluntary disclosure commits the company to a full internal investigation. The company must hire external counsel, audit years of international transactions, and turn over all evidence to the DOJ. These investigations often cost far more than the final government penalty.
Individual Prosecution Risk: To secure cooperation credit, the company must identify complicit individuals. If the company cannot obtain cooperation from foreign sales managers or distributors, it may struggle to satisfy the DOJ's cooperation standards.
The June 2025 Prioritization Filter: If the discovered misconduct is minor, isolated, and has no national security or cartel links, the company's counsel may assess that the DOJ would decline to prosecute under its June 2025 Guidelines even if they discovered it. However, this is a high-risk gamble; if the government discovers the issue independently (e.g., through a competitor's whistleblowing), the company loses all disclosure credits.

Cross-Jurisdictional Alignment: UK, China, and Beyond

An effective compliance program cannot focus solely on US law. Medtech manufacturers must navigate overlapping national anti-bribery frameworks:

1. The UK Bribery Act 2010 (UKBA)

For companies with a business presence in the United Kingdom, the UKBA represents a stricter standard than the FCPA:

No Facilitation Payments: The UKBA contains no exception for "facilitation" or "grease" payments; all bribery, regardless of size, is illegal.
Commercial Bribery: The UKBA prosecutes private-to-private bribery (e.g., bribing a private hospital doctor or purchasing manager), whereas the FCPA is limited to bribing public officials.
Section 7 strict Liability: A commercial organization is strictly liable if an associated person (such as a foreign distributor) bribes another person to win business. The only defense is proving the company had "adequate procedures" in place, which requires demonstrating the onboarding and transaction controls described above.

2. China SAMR and NHC Regulations

China is a critical market for medtech, but its domestic anti-bribery enforcement is intense:

Unit Bribery: Under the PRC Criminal Law, if a distributor or manufacturer pays bribes to win hospital tenders, both the individuals and the corporation can be prosecuted for "unit bribery."
National Health Commission (NHC) "Three-Fixed" Rules: State hospitals enforce strict rules regarding when and how medical representatives can meet with physicians, requiring meetings to be pre-registered, pre-approved, and held in public areas.
SAMR Crackdowns: The State Administration for Market Regulation (SAMR) routinely audits distributor pricing. If a manufacturer grants excessive discounts to a distributor, SAMR may interpret that discount as a kickback designed to facilitate bribery.

To ensure alignment across these frameworks, compare these strategies with the FTC antitrust and medical device M&A 2025-2026 guide to understand how corporate transactions and distributor consolidation are evaluated by global regulators.

Frequently Asked Questions

Does the FCPA apply if we only sell through independent foreign distributors and never pay foreign officials directly?

Yes. The FCPA explicitly prohibits payments made through third parties while "knowing" that all or a portion of the payment will be offered to a foreign official. The statute defines "knowing" to include conscious disregard, willful blindness, or deliberate ignorance. If you grant an unusually high discount to a distributor without auditing their local practices, or if you ignore red flags, the DOJ and SEC will hold the manufacturer liable under the books-and-records and internal-controls provisions.

Are doctors at government-owned hospitals really "foreign officials" under the FCPA?

Yes. In countries with nationalized healthcare systems or state-owned hospitals, the facility is classified as an "instrumentality" of the foreign government. Because the doctors, surgeons, hospital administrators, and laboratory directors are employees of that state instrumentality, they meet the statutory definition of "foreign officials." This interpretation has been repeatedly validated by US federal courts and is the basis of almost all healthcare-sector FCPA prosecutions.

Is FCPA enforcement still active after the 2025 pause, and does the Trump-era shift make medtech safer?

Yes, enforcement remains active. The 180-day pause signed under EO 14209 ended on June 9, 2025 when Deputy Attorney General Todd Blanche issued new Guidelines. The new guidelines did not repeal the FCPA; instead, they focused resources on key priorities: protecting US companies from foreign bribery, safeguarding national security, and addressing systemic corporate misconduct. The shift does not make non-compliant companies safer; rather, it increases the importance of robust internal controls, as large-scale tender bribery remains a top prosecution priority under the "fair opportunities" prong.

What is the single highest-risk payment pattern for device companies selling abroad?

The highest-risk pattern is the unauthorized or excessive distributor discount. When a manufacturer grants a discount that exceeds standard commercial rates (e.g., giving a 70% discount instead of the standard 35%) to a distributor in a high-risk country, and that discount is approved without a verified, documented business reason, it creates a pool of local cash. The distributor can easily route this margin spread to public hospital doctors or tender board members, with the manufacturer facing strict liability under the books-and-records provisions.

How does the FCPA interact with the UK Bribery Act and local anti-bribery laws in our target markets?

A single corrupt payment by a distributor can trigger multiple, parallel investigations. For example, a bribe paid to a doctor in London or Shanghai can violate the US FCPA (due to the company's US listing), the UK Bribery Act (due to the company's UK operations), and domestic Chinese anti-bribery laws (PRC Criminal Law and SAMR rules). A compliant compliance program must align with the strictest standard across these jurisdictions, which means prohibiting facilitation payments, auditing distributor margins, and enforcing fair market value limits globally.

Disclaimer

This guide is for educational and informational purposes only. The information provided does not constitute legal, regulatory, or compliance advice for any specific product, transaction, or company. The regulatory and legal landscapes under the Foreign Corrupt Practices Act, the Department of Justice, and the Securities and Exchange Commission are dynamic and subject to change. Manufacturers and compliance professionals should consult qualified legal counsel to design and audit their specific anti-bribery compliance programs.